lifestyle.faithfamilyamerica.com

Author: BriaCell Therapeutics Corp.

BriaCell Adds NYU Langone Health’s Perlmutter Cancer Center as Clinical Site in Pivotal Phase 3 Breast Cancer Study

May 7, 2026
BriaCell Receives FDA Clearance to Initiate Bria-BRES+™ Clinical Study in Breast Cancer

May 6, 2026
BriaCell Announces Six Clinical Data Presentations at ASCO 2026

April 27, 2026
BriaCell Presents Robust Anti-Cancer Activity of Bria-OTS+™ in Preclinical Cancer Models

April 21, 2026
BriaCell Presents Positive Phase 3 Quality of Life and Phase 2 Biomarker Data at the 2026 AACR Meeting

April 20, 2026
BriaCell and BriaPro Announce Closing of Asset Purchase Transaction for Exclusive Soluble CD80 License

March 31, 2026
BriaCell to Present Positive Clinical Data for Bria-IMT™ and Preclinical Data for Next Generation Bria-OTS+™ Personalized Immunotherapy at the 2026 AACR Conference

March 18, 2026
BriaCell to Present Four Poster Presentations at the 2026 AACR Annual Meeting

March 10, 2026
BriaCell Therapeutics Corp. Announces Results of Shareholder Meeting

March 5, 2026
BriaCell and BriaPro Enter Into Asset Purchase Agreement for Exclusive Soluble CD80 License

February 18, 2026